This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Nathan Bahary, MD, University of Pittsburgh Identifier:
First received: September 12, 2005
Last updated: January 15, 2016
Last verified: January 2016
This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.

Condition Intervention Phase
Cancer Drug: Gefitinib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Resource links provided by NLM:

Further study details as provided by Nathan Bahary, MD, University of Pittsburgh:

Primary Outcome Measures:
  • Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.

Secondary Outcome Measures:
  • Determine the response rate, time to disease progression, survival rate at 6- month intervals after treatment start, and safety profile of Gefitinib and docetaxel as treatment for advanced pancreatic cancer
  • Determine the time course of serial CA19-9 measurements during treatment.

Estimated Enrollment: 45
Study Start Date: September 2004
Study Completion Date: December 2006
Detailed Description:
Initial therapy for metastatic pancreatic carcinoma is inadequate, and there is no effective second line therapy. Docetaxel has known single agent activity in pancreatic carcinoma, resulting in a median survival of 5.9 months, similar to gemcitabine, when assessed in Phase II studies (10) and pancreatic tumors are known to express EGFR. We propose that the combination of docetaxel with Gefitinib will have activity against pancreatic carcinoma, whether the regimen is administered as first or second-line therapy for metastatic disease. Given the toxicity profiles of both agents, we believe this will be a well-tolerated regimen. In fact, preliminary analysis of a phase II study of docetaxel and Gefitinib with an identical regimen in non-small cell lung cancer patients showed this regimen to be safe and active.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the pancreas that is surgically inoperable
  • Must have had one prior chemotherapeutic regimen for advanced disease (Prior radiation with a radiation sensitizer for locally advanced disease or adjuvant therapy is not considered a prior regimen for purpose of this study)
  • Disease must be measurable by RECIST criteria; measurable disease will be defined as at least one lesion that can be accurately measured in at least one dimension measuring at least 2 cm conventional CT or MRI or 1 cm with spiral CT scans (Appendix A)
  • Aged 18 years or older
  • ECOG performance status of 0 - 2 (see Appendix B)
  • Able to take oral medications without difficulty
  • Adequate bone marrow function as evidenced by an ANC > 1500/mL and platelet count > 100, 000/mL
  • Adequate renal function as evidenced by serum creatinine within institutional limits or creatinine clearance > 60 ml/minute if above upper institutional limits (ULN)
  • Adequate hepatic function as evidenced by ALT, AST, and total bilirubin within ULN. If hepatic metastases are present, ALT and AST may be up to 5 x ULN.
  • Provision of written informed consent
  • Men and women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy. This is a precautionary measure for use of Gefitinib and docetaxel.

Exclusion Criteria:

  • Known severe hypersensitivity to Gefitinib or docetaxel or any of the excipients of these products (i.e. polysorbate 80)
  • Previous treatment with Gefitinib or docetaxel.
  • Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or cervical cancer in situ.
  • Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's Wort
  • Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.
  • Treatment with radiation therapy or chemotherapy within 28 days before Day 1 of trial treatment
  • Any unresolved chronic toxicity greater then CTC grade 2 from previous anticancer therapy (except alopecia)
  • Incomplete healing from previous oncologic or other major surgery.
  • Pregnancy or breast feeding (women of childbearing potential).
  • Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).
  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
  • Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00177242

United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Kenneth Foon, MD University of Pittsburgh
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nathan Bahary, MD, Associate Professor, University of Pittsburgh Identifier: NCT00177242     History of Changes
Other Study ID Numbers: 04-027
Study First Received: September 12, 2005
Last Updated: January 15, 2016

Keywords provided by Nathan Bahary, MD, University of Pittsburgh:

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on June 22, 2017